公开(公告)号：US20180111986A1

公开(公告)日：2018-04-26

申请号：US15534635

申请日：2015-12-11

Applicant: AMGEN INC. ,  UCB PHARMA S.A.

Inventor： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC: C07K16/22 ,  A61P19/08 ,  A61K39/395 ,  A61K45/06 ,  A61P19/10

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P19/08 ,  A61P19/10 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

公开(公告)号：US11851483B2

公开(公告)日：2023-12-26

申请号：US15534635

申请日：2015-12-11

Applicant: AMGEN INC. ,  UCB PHARMA, S.A.

Inventor： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC: A61K39/395 ,  C07K16/22 ,  A61P19/08 ,  A61P19/10 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61P19/08 ,  A61P19/10 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.